Recurrence of atopic dermatitis after dupilumab discontinuation: a systematized review
DOI:
https://doi.org/10.35381/s.v.v10i2.5259Keywords:
Dermatitis, atopic, antibodies, monoclonal, humanized, recurrence, withholding treatment, eczema, (Source: DeCS).Abstract
Dupilumab controls moderate-to-severe atopic dermatitis, but what happens after it is stopped remains uncertain. Objective: To analyze the evidence on recurrence of atopic dermatitis after discontinuation or dose spacing of dupilumab. Method: Systematized review in PubMed/MEDLINE and SciELO with predefined eligibility criteria; 5 studies were selected. Results: In a randomized trial, only 30.4% of patients switched to placebo maintained an EASI-75 response at 36 weeks, compared with 71.6% of those who continued. In clinical practice, recurrence after discontinuation ranged from 23.4% to 42.8%, with a median of 29 to 47 weeks; dose tapering was successful in 83.3% of patients with low disease activity. Conclusion: Recurrence is frequent but not universal; gradual dose spacing is safer than abrupt discontinuation.
Downloads
References
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-48. https://doi.org/10.1056/NEJMoa1610020
Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409-31. https://doi.org/10.1111/jdv.18345
Briceño-Casado MP, Ríos-Sánchez E, Gil-Sierra MD. Datos en vida real a largo plazo de dupilumab en dermatitis atópica. Rev OFIL ILAPHAR. 2020;30(1):25-7. https://doi.org/10.4321/s1699-714x2020000100008
Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131-43. https://doi.org/10.1001/jamadermatol.2019.3617
Chen M, Wen X, Liu J, Yang G, Li Q, Jiang Z, et al. Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis. Front Med (Lausanne). 2025;12:1585368. https://doi.org/10.3389/fmed.2025.1585368
Barei F, et al. Clinical course of atopic dermatitis after dupilumab discontinuation: a multicenter real-world study. Clin Exp Dermatol. 2025:llaf275. https://doi.org/10.1093/ced/llaf275
Palomo Palomo C, Guerra Estévez D, Ganfornina Andrades A, Parrado González A, Romero Alonso MM, Reyes Malia M. Efectividad, seguridad y calidad de vida de dupilumab en la dermatitis atópica. Rev OFIL ILAPHAR. 2025;35(4):375-80. https://doi.org/10.4321/s1699-714x2025000400014
Matsutani M, Imai Y, Miyamoto S, Inoue Y, Natsuaki M, Kanazawa N. Real-world efficacy of dupilumab re-administration after discontinuation in patients with atopic dermatitis. J Cutan Immunol Allergy. 2024;7:12480. https://doi.org/10.3389/jcia.2024.12480
Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023;189(3):327-35. https://doi.org/10.1093/bjd/ljad159
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Verónica Pamela Rosero-Buitrón, Angela Priscila Gutiérrez-Bedón, Denice Stefany Fares-Cedeño, Hillary Marian Martillo-Garcia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
